PUBLISHED

Mortality Experience in the Elderly in the Impairment Study Capture System (ISCS). Thomas Ashley, MD, FACP; Clifton P. Titcomb,Jr. MD; Anna Hart, MS; Richard Bergstrom, FSA, MAAA.

MMLC - ISCS Aviation and Hazardous Sports Study.
Bradley T. Roudebush; Anthony F. Milano, MD, MPH; Anna R. Hart, MS, SRM.

Mortality and Morbidity Liaison Committee – ISCS Body Mass Index Study: Brad Roudebush, FSA, MAAA; Thomas Ashley, MD, FACP; Clifton P. Titcomb Jr., MD. Journal of Insurance Medicine: Vol. 38, No. 3, pp. 167–180. (September 2006)

This study used the Impairment Study Capture System (ISCS) to examine the relationship between mortality and body mass index (BMI) in an insured population, particularly BMI in isolation from other risk factors.


(Excerpts) A Descriptive Index of Mortality Studies from Selected Sources 1951-1995: Richard B. Singer, MD; Michael W. Kita, MD; John R. Avery, Director Emeritus, Center for Medico-Actuarial Statistics, MIB, Inc. SOA/AAIM/HOLUA-IHOU, Mortality and Morbidity Liaison Committee and MIB,Inc. Published by the Center for Medico-Actuarial Statistics of MIB,Inc. Copyright © 2001 by MIB, Inc. (click here to order publication).

Mortality Study of Policies on Insured Lives With Diabetes Mellitus Known at Time of Issue: Anthony F. Milano, MD, MA, MPH; Tom Rhodes, FSA, MAAA; Anna Hart, MS; Douglas Ingle, FALU, FLMI; Paul Howman, FLMI; David Winsemius, MD, MPH; Richard Bergstrom, FSA, MAAA; Clifton P. Titcomb Jr., MD. Journal of Insurance Medicine: Vol. 37, No. 2, pp. 89–100. (April 2005)

This is an Impairment Study Capture System (ISCS) study of contemporary diabetes mellitus mortality among insured lives. Because the diagnosis and treatment of diabetes has changed during the last 15 years, many applicants may be expected to exhibit more favorable outcomes than in the past. The study covers policy-years durational experience extending to only 10 years.

Alcohol Abuse and Liver Enzymes (AALE): Results of an Intercompany Study of Mortality: Clifton Titcomb MD; Richard Braun, MD; Brad Roudebush, FSA; Jess Mast, Harry Woodman, FSA. For the Mortality Liaison Committee of the Society of Actuaries (SOA), the American Academy of Insurance Medicine (AAIM), and the Academy of Life Underwriting (ALU). Journal of Insurance Medicine: Vol. 33, No. 3, pp. 277–289. (July 2001)

Evaluation of applicants for life insurance who have elevations of their liver function tests or an increased probability of alcohol abuse has always been difficult for underwriters. This paper reports the results of an intercompany study in which the pooled mortality experience of a group of insureds with evidence of alcohol abuse, an adverse driving record or elevations of the liver transaminases or gamma-glutamyl transferase is summarized.

Study of Policies on Insured Lives With Elevated Blood Pressure Known at Time of Issue: Harry Woodman, FSA; Jess Mast, BA; Anthony Milano, MD; Douglas Ingle, FALU; Richard Bergstrom, FSA; Anna Hart, MS, SRM; Nancy J. Hoffman, FLMI. Journal of Insurance Medicine: Vol. 35, No. 2, pp. 72–84. (April 2003)

The mortality results of policies on insured lives with elevated blood pressure have been the subject of several studies since the early 20th century. This study, which began with issues of 1989, utilizes data from the Impairment Study Capture System (ISCS). Data are also compiled for impairments other than elevated blood pressure in the ISCS for the same study period. A comparison of these 2 sets of data shows the relative severity of elevated blood pressure compared to all other impairments combined. The determination of elevated blood pressure was made on the basis of risk classification due to lack of specific blood pressure readings.

Updated 1/7/2010